Commercial Bank OF Ethiopia Pharmaceutical Import Profile — Ethiopia (DGFT 2022–2026)

Name: Commercial Bank OF Ethiopia Pharmaceutical Import Records from India — 10 Products, $2.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Commercial Bank OF Ethiopia — Pharmaceutical Importer Profile (2026) | 10 Products, $2.1M Trade | TransData Nexus

Commercial Bank OF Ethiopia

Pharmaceutical Importer · Ethiopia · Diabetes & Endocrine Focus · $2.1M Total Trade · DGFT Verified

Commercial Bank OF Ethiopia is a pharmaceutical importer based in Ethiopia with a total trade value of $2.1M across 10 products in 7 therapeutic categories. Based on 44 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Commercial Bank OF Ethiopia sources from 35 verified Indian suppliers, with Mylan Laboratories Limited accounting for 17.8% of imports.

Commercial Bank OF Ethiopia — Import Portfolio & Supplier Network

Commercial Bank OF Ethiopia import network — 10 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Commercial Bank OF Ethiopia?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Mylan Laboratories Limited	$1.5M	37	17.8%
Neon Laboratories Limited	$1.2M	44	14.7%
Brawn Laboratories Limited

What Formulations Does Commercial Bank OF Ethiopia Import?

Formulation	Value	Ships
Veterinary medicinal preparations not	$248.4K	9
Pharma drugs and medi neutas 300ug/0.5mlpfs(et) (qt. 21169 pfs	$150.0K	3
Tenofovir disoproxil fumarate+lamivudinenos	$150.0K	3
Herine (heparin sodium injection USP 25000iu/5ML) (5000iu/ML) - 5 ML	$150.0K	3
Stop tb kit i & iii(rifampicin 150MG+isoniazid75mg+pyrazinamide400mg+ethambutol275mg)-6x28t+(rifa.150MG+iso.75MG	$150.0K	3
Each film coated tablet conts:spironolactone USP 25MG,batch# bnt0424041-44,bnt0424046-47,d/m-04/24	$146.5K	3
Tenofovir disoproxil fumarate 300MG + lamivudine 300MG tablets (30's)(57448 packs x 30 nos	$143.4K	3
Tramadol injection BP 50MG/ML-2ML- supridol 10,62,930 ampoules: 106,293 packs x02 x 05	$141.4K	3
Oxytetracycline hydrochloride,hydrocortisone acetate & polymyxin b sulphate eye/ear suspension Each ML	$139.5K	3
Sterile ceftriaxone sodium USP	$134.3K	3
Morphine sulfate injection BP 10MG/ML, 1ML- neomorph 382,620 ampoules: 38,262 packs x 02 x 05	$124.6K	3
Sosrane isoflurane USP 250ML (liquid	$100.0K	2
Aneket ketamine hydrochloride	$100.0K	2
Vancomycin hydrochloride	$100.0K	2
Meropenem for injection USP 1g with	$100.0K	2

Commercial Bank OF Ethiopia imports 202 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 10 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Insulin	Diabetes & Endocrine	$650.0K	13	0.9%	5
2	Kit	Medical Devices & Diagnostics	$450.0K	9	0.1%	9
3	Syringe	Medical Devices & Diagnostics	$200.0K	4	0.1%	8
4	Atazanavir	Antiviral & HIV Medications	$150.0K	3	0.2%	10
5	Meropenem	Advanced Antibiotics	$150.0K	3	0.1%	15
6	Tetracycline	Antibiotics	$150.0K	3	0.9%	11
7	Morphine	Analgesics & Antipyretics	$124.6K	3	0.7%	2
8	Darunavir	Antiviral & HIV Medications	$100.0K	2	0.2%	11
9	Bleomycin	Advanced Oncology	$78.7K	2	1.4%	12
10	Mercaptopurine	Advanced Oncology	$39.2K	2	6.7%	2

Commercial Bank OF Ethiopia imports 10 pharmaceutical products across 7 categories into Ethiopia totaling $2.1M.

Commercial Bank OF Ethiopia — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

The Commercial Bank of Ethiopia (CBE) is a state-owned financial institution headquartered in Addis Ababa, Ethiopia. Established in 1963, CBE has grown to become the largest commercial bank in the country, offering a wide range of banking services, including savings and checking accounts, loans, and foreign exchange services. While primarily a financial entity, CBE has also engaged in the importation of pharmaceutical products, positioning itself as a significant player in Ethiopia's pharmaceutical supply chain. This involvement underscores the bank's diversified operations and its commitment to supporting the nation's healthcare sector.

2Distribution Network

CBE's distribution network for pharmaceutical imports is not publicly detailed. However, as a major financial institution, the bank likely leverages its extensive infrastructure, including branches and financial networks, to facilitate the importation and distribution of pharmaceutical products. This strategic approach enables efficient logistics and broad geographic coverage within Ethiopia, ensuring that imported medicines reach various regions effectively.

3Industry Role

In Ethiopia's pharmaceutical supply chain, CBE functions as an importer and distributor of finished pharmaceutical formulations. By sourcing medicines from international suppliers, particularly from India, the bank plays a crucial role in enhancing the availability of essential drugs in the Ethiopian market. This involvement supports the healthcare system by ensuring a steady supply of medications across the country.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Commercial Bank OF Ethiopia

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

CBE's pharmaceutical imports from India total $2.1 million USD across 44 shipments, encompassing 10 products across 7 therapeutic categories. The top five products imported include insulin ($650K), kits ($450K), syringes ($200K), atazanavir ($150K), and meropenem ($150K). The bank's portfolio concentration is notable, with the top five products accounting for 76.5% of the total import value. This high concentration suggests a strategic focus on specific high-demand medications, potentially optimizing procurement and distribution processes. However, such concentration also indicates a dependency on a limited range of products, which could pose risks if market dynamics change or if there are disruptions in the supply chain.

2Supply Chain Resilience

CBE's supply chain resilience is influenced by its reliance on a select group of Indian suppliers. The top five suppliers—Mylan Laboratories Limited, Neon Laboratories Limited, Brawn Laboratories Limited, Naprod Life Sciences Private Limited, and VHB Medi Sciences Limited—collectively account for a significant portion of the import value. This concentrated supplier base may enhance negotiation leverage and streamline logistics. However, it also exposes the bank to potential risks associated with supplier disruptions, such as production delays or regulatory issues. To mitigate these risks, CBE may consider diversifying its supplier base and establishing relationships with additional manufacturers to ensure a more resilient supply chain.

Importing Pharmaceuticals into Ethiopia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Ethiopia

1Regulatory Authority & Framework

The Ethiopian Food and Drug Authority (EFDA) is the national regulatory body responsible for ensuring the safety, quality, and efficacy of medicines, medical devices, and other health-related products in Ethiopia. Established under Proclamation No. 1263/2021 and defined under Regulation No. 531/2023, EFDA's mandate includes the registration, licensing, and inspection of pharmaceutical products and establishments. EFDA's role is critical in safeguarding public health by regulating the importation and distribution of pharmaceutical products. (efda.gov.et)

2Import Licensing & GMP

Importers of pharmaceutical products into Ethiopia must obtain an import permit from EFDA. This process involves submitting an application through EFDA's electronic regulatory information system, i-Import, which streamlines the approval submission and review process. Additionally, EFDA requires that manufacturers provide a valid Good Manufacturing Practice (GMP) certificate or a waiver letter before issuing marketing authorization for imported medicines. The GMP certificate ensures that the manufacturing facilities adhere to internationally recognized quality standards. (efda.gov.et)

3Quality & Labeling

Commercial Bank OF Ethiopia — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

CBE's focus on importing specific high-demand pharmaceutical products, such as insulin, kits, syringes, atazanavir, and meropenem, aligns with the critical healthcare needs in Ethiopia. The bank's import strategy is driven by market demand for these essential medications, which are vital for managing chronic conditions like diabetes and for treating infections. By concentrating on these therapeutic areas, CBE aims to address significant health challenges in the country and ensure the availability of necessary treatments.

2Sourcing Profile

CBE's sourcing strategy emphasizes importing finished pharmaceutical formulations from India, a country known for its robust pharmaceutical manufacturing sector. The bank's focus on specific therapeutic categories suggests a targeted approach to procurement, ensuring that the imported products meet the therapeutic needs of the Ethiopian population. India's adherence to international quality standards and its competitive pricing make it a strategic partner for CBE in fulfilling Ethiopia's pharmaceutical requirements.

3Market Positioning

Through its importation of essential pharmaceutical products, CBE serves multiple segments of the Ethiopian market, including retail pharmacies, hospitals, and government health institutions. By ensuring the availability of critical medications, the bank supports the healthcare infrastructure and contributes to the overall health and well-being of the Ethiopian population.

Seller's Guide — How to Become a Supplier to Commercial Bank OF Ethiopia

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with CBE, especially if they can offer a broader range of pharmaceutical products that complement the bank's existing imports. Identifying gaps in CBE's current sourcing, such as unmet therapeutic needs or emerging health challenges, presents avenues for new suppliers to introduce innovative solutions. Establishing partnerships with CBE could enhance market access and strengthen the presence of Indian pharmaceutical products in Ethiopia.

2Requirements & Qualifications

Indian exporters seeking to supply pharmaceutical products to CBE and the Ethiopian market must ensure that their products are registered with EFDA and comply with Ethiopian regulatory standards. This includes obtaining a valid GMP certificate or a waiver letter from EFDA, ensuring that products meet EFDA's quality and safety standards, and adhering to labeling requirements in Amharic. Additionally, exporters should be prepared to participate in EFDA's electronic regulatory information system, i-Import, for the import approval process. (efda.gov.et)

3How to Approach

Frequently Asked Questions — Commercial Bank OF Ethiopia

What products does Commercial Bank OF Ethiopia import from India?

Commercial Bank OF Ethiopia imports 10 pharmaceutical products across 7 categories. Top imports: Insulin ($650.0K), Kit ($450.0K), Syringe ($200.0K), Atazanavir ($150.0K), Meropenem ($150.0K).

Who supplies pharmaceuticals to Commercial Bank OF Ethiopia from India?

Commercial Bank OF Ethiopia sources from 35 verified Indian suppliers. The primary supplier is Mylan Laboratories Limited (17.8% of imports, $1.5M).

What is Commercial Bank OF Ethiopia's total pharmaceutical import value?

Commercial Bank OF Ethiopia's total pharmaceutical import value from India is $2.1M, based on 44 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Commercial Bank OF Ethiopia focus on?

Commercial Bank OF Ethiopia imports across 7 categories. The largest: Diabetes & Endocrine (31.1%), Medical Devices & Diagnostics (31.1%), Antiviral & HIV Medications (11.9%).

Get Full Commercial Bank OF Ethiopia Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.